Popular new glucagon-like peptide 1 receptor agonists require some pre-procedure considerations but not necessarily discontinuation of the drugs to support the ...
(Reuters) - The U.S. Food and Drug Administration (FDA) on Tuesday published letters warning two online vendors to stop selling ...
(Reuters) - Slim Jim beef jerky maker Conagra Brands said on Thursday it may consider changing portion sizes of its ...
Antidiabetic drug tirzepatide (Mounjaro) shows superiority over semaglutide (Ozempic, Wegovy, and Rybelsus) in controlling blood glucose as well as in ...
A small, nonmechanical, implanted device that continuously releases the glucagon-like peptide-1 (GLP-1) receptor agonist exenatide (Byetta, Bydureon) and designed for ...
Use of GLP-1 agonists, such as semaglutide, surged among US adults with type 2 diabetes in recent years, through March ...
TOPLINE: Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use lowers the risk for death, cardiovascular disease, decompensated cirrhosis, and liver failure ...
SAN DIEGO – Higher doses of oral semaglutide than the 14-mg/day dose that is currently approved for type 2 diabetes ...
© Pharma News Hubb All rights reserved.
Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.